In the current study, we show that SREBP-1 mediated lipogenic pathway is a key mediator of oncogenic EGFR and that its constitutive activation contributes to gefitinib-acquired resistance in EGFR mutant lung cancer. Here, EGFR is linked to lung carcinoma.